|
Alabama
|
SB 174 "Carly's Law" (Act 2014-277) Allows University of Alabama Birmingham to conduct effectiveness research using low-THC products for treating seizure disorders for up to 5 years. Not operational as of April, 2015.
|
|
Only the Univ. Alabama Birmingham is allowed to dispense FDA-approved trial products with the proper permissions.
|
Yes, debilitating epileptic conditions or life-threatening seizures.
|
No
|
Extracts that are low THC= below 3% THC
|
Yes
|
Yes
|
|
Florida
|
|
Yes
|
Yes, 5 registered nurseries across the state by region, which have been in business at least 30 years in Florida.
|
Yes, cancer, medical condition or seizure disorders that chronically produces symptoms that can be alleviated by low-THC products
|
No
|
Cannabis with low THC= below .8% THC and above 10% CBD by weight
|
|
Yes, with approval from 2 doctors
|
|
Georgia
|
|
Yes
|
Law allows University System of Georgia to develop a lot THC oil clinical research program that meets FDA trial compliance.
|
Yes, end stage cancer, ALS, MS, seizure disorders, Crohn's, mitochondrial disease, Parkinson's, Sickle Cell disease
|
No
|
Cannabis oils with low THC= below 5% THC and at least an equal amount of CDB.
|
Yes
|
Yes
|
|
Iowa
|
|
Yes
|
Doesn't define or provide in-state methods of access or production.
|
Yes, intractable epilepsy
|
No
|
"Cannabidiol- a non-psychoactive cannabinoid" that contains below 3% THC, no more than 32 oz, and essentially free from plant material.
|
Yes
|
Yes
|
|
Idaho- VETOED BY GOVERNOR
|
SB 1146 (VETOED by governor 4/16/15)
|
No
|
Doesn't define.
|
The possessor has, or is a parent or guardian of a person that has, cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, fibroymyalgia, Parkinson's disease or sickle cell disease;
|
No
|
Is composed of no more than three-tenths percent (0.3%) tetrahydrocannabidiol by weight; is composed of at least fifteen (15) times more cannabidiol than tetrahydrocannabidiol by weight; and contains no other psychoactive substance.
|
Yes
|
Yes
|
|
Kentucky
|
SB 124 (2014) Clara Madeline Gilliam Act
Exempt cannabidiol from the definition of marijuana and allows it to be administerd by a public university or school of medicine in Kentucky for clinical trial or expanded access program approved by the FDA.
|
No
|
Universities in Kentucky with medical schools that are able to get a research trial. Doesn't allow for in-state production of CBD product.
|
Intractable seizure disorders |
No
|
No, only "cannabidiol".
|
|
|
|
Louisiana
|
SB 143 The "Alison Neustrom Act"
Please see bolded comment to the right.
|
|
Louisiana State Univ. and the Southern Univ. Agricultural Center have the right of first refusal to be the licensed production facility. If they pass, it opens up to a competitive bid process.
|
Yes
|
No
|
NCSL counts this act as a low-THC program based on this statement in the enacted legislation. "THC shall be reduced to the lowest acceptable therapeutic levels available through scientifically acceptable methods."
NCSL also does NOT count this program as "comprehensive" because it does not allow for the combustion or vaporizing of flowered product.
Other organizations or groups may count this as a comprehensive program, but please refer to NCSL's definitions above. NCSL will reconsider its categorization based on final rules, regulations and practice when they are finalized.
|
Yes
|
Yes
|
|
Mississippi
|
|
|
All provided through National Center for Natural Products Research at the Univ. of Mississippi and dispensed by the Dept. of Pharmacy Services at the Univ. of Mississippi Medical Center
|
Yes, debilitating epileptic condition or related illness
|
No
|
"CBD oil" - processed cannabis plant extract, oil or resin that contains more than 15% cannabidiol, or a dilution of the resin that contains at least 50 milligrams of cannabidiol (CBD) per milliliter, but not more than one-half of one percent (0.5%) of tetrahydrocannabinol (THC)
|
Yes, if an an authorized patient or guardian
|
Yes
|
|
Missouri
|
|
Yes
|
Yes, creates cannabidiol oil care centers and cultivation and production facilities/laboratories.
|
Yes, intractable epilepsy that has not responded to three or more other treatment options.
|
No
|
"Hemp extracts" equal or less than .3% THC and at least 5% CBD by weight.
|
Yes
|
Yes
|
|
North Carolina
|
HB 1220 (2014) Epilepsy Alternative Treatment Act- Pilot Study
|
Yes
|
University research studies with a hemp extract registration card from the state DHHS or obtained from another jurisdiction that allows removal of the products from the state.
|
Yes, intractable epilepsy
|
No
|
"Hemp extracts" with less than three-tenths of one percent (0.3%) tetrahydrocannabinol (THC) by weight.
Is composed of at least ten percent (10%) cannabidiol by weight.
Contains no other psychoactive substance.
|
Yes
|
Yes
|
|
Oklahoma
|
|
Yes
|
No in-state production allowed, so products would have to be brought in. Any formal distribution system would require federal approval.
|
People under 18 (minors) Minors with Lennox-Gastaut Syndrome, Dravet Syndrome, or other severe epilepsy that is not adequately treated by traditional medical therapies
|
No
|
A preparation of cannabis with no more than .3% THC in liquid form.
|
Yes
|
Yes, only allowed for minors
|
|
South Carolina
|
SB 1035 (2014) Medical Cannabis Therapeutic Treatment Act- Julian's Law
|
Yes |
Must use CBD product from an approved source; and
(2) approved by the United States Food and Drug Administration to be used for treatment of a condition specified in an investigational new drug application.
-The principal investigator and any subinvestigator may receive cannabidiol directly from an approved source or authorized distributor for an approved source for use in the expanded access clinical trials.
Some have interpreted the law to allow patients and caregivers to produce their own products.
|
Lennox-Gastaut Syndrome, Dravet Syndrome, also known as severe myoclonic epilepsy of infancy, or any other form of refractory epilepsy that is not adequately treated by traditional medical therapies.
|
No
|
Cannabidiol or derivative of marijuana that contains 0.9% THC and over 15% CBD, or least 98 percent cannabidiol (CBD) and not more than 0.90% tetrahydrocannabinol (THC) by volume that has been extracted from marijuana or synthesized in a laboratory
|
Yes
|
Yes
|
|
Tennessee
|
SB 2531 (2014)
Creates a four-year study of high CBD/low THC marijuana at TN Tech Univ.
______
|
Researchers need to track patient information and outcomes
______
No
|
Only products produced by Tennessee Tech University.
Patients may possess low THC oils only if they are purchased "legally in the United States and outside of Tennessee," from an assumed medical cannabis state, however most states do not allow products to leave the state.
_____
Allows for legal defense for having the product as long as it was obtained legally in the US or other medical marijuana state.
|
Yes, intractable seizure conditions.
______
Yes, intractable seizure conditions.
|
No
______
No
|
"Cannabis oil" with less than .9% THC as part of a clinical research study
______
Same as above.
|
Yes
|
Yes
|
|
Texas
|
SB 339 (2015)
Texas Compassionate Use Act
|
Yes
|
Yes, licensed by the Department of Public Safety.
|
Yes, intractable epilepsy.
|
No
|
"Low-THC Cannabis" with not more than 0.5 percent by weight of tetrahydrocannabinols; and not less than 10 percent by weight of cannabidiol
|
Yes
|
Yes
|
|
Utah
|
HB 105 (2014) Hemp Extract Registration Act
|
Yes
|
Not completely clear, however it may allows higher education institution to grow or cultivate industrial hemp
|
Yes, intractable epilepsy that hasn't responded to three or more treatment options suggested by neurologist
|
No
|
"Hemp extracts" with less than .3% THC by weight and at least 15% CBD by weight and contains no other psychoactive substances
|
Yes
|
Yes
|
|
Virginia
|
|
No |
No in-state means of acquiring cannabis products.
|
Intractable epilepsy
|
No
|
Cannabis oils with at least 15% CBD or THC-A and no more than 5% THC.
|
Yes
|
Yes
|
|
Wisconsin
|
|
No
|
Physicians and pharmacies with an investigational drug permit by the FDA could dispense cannabidiol. Qualified patients would also be allowed to access CBD from an out-of-state medical marijuana dispensary that allows for out-of-state patients to use their dispensaries as well as remove the products from the state.
No in-state production/manufacturing mechanism provided.
|
Seizure disorders
|
|
Exception to the definition of prohibited THC by state law, allows for possession of "cannabidiol in a form without a psychoactive effect." THC or CBD levels are not defined.
|
No
|
Yes
|
|
Wyoming
|
HB 32 (2015)
Supervised medical use of hemp extracts. Effective 7/1/2015
|
Yes
|
No in-state production or purchase method defined.
|
Intractable epilepsy or seizure disorders
|
No
|
"Hemp extracts" with less than 0.3% THC and at least 5% CBD by weight.
|
Yes
|
Yes
|